Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Fibriant General Information
Fibriant has developed a recombinant manufacturing platform for producing specific variants of human fibrinogen and active thrombin. Its lead product, RecoSeel™, is a fully recombinant fibrin-based topical hemostat for surgical bleeding. The company also has pipeline programs targeting MRSA infections and regenerative medicine, supported by significant EIC Accelerator funding. No published clinical results yet.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Leiden, South Holland
Netherlands
Netherlands
Drug Pipeline
RECOFIB
Pre-clinicalKey Partnerships
Netherlands Organization for Applied Scientific Research (TNO), Academic collaborations with University of Leiden and other institutions in the field of hemostasis and tissue repair
Fibriant Funding
No funding data available
To view Fibriant's complete valuation and funding history, request access »